In metastatic intestinal or pancreatic NETs, lanreotide reduced tumor growth rate versus placebo at 12 weeks (difference -2.9, interval -5.1 to -0.8, p = 0.008), maintained at most later visits.
In plain wordsIn patients with metastatic intestinal or pancreatic NETs, lanreotide reduced tumor growth rate versus placebo by 12 weeks.
- Peptide
- Lanreotide
- Outcome
- DecreaseTumor growth rate
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Tumor growth · Cancer
- Studied dose
- 120 mg every 4 weeks · Assessed at 12 weeks, within a 96-week treatment periodAs given in this study (human).
Measurements
- Difference in least-square mean TGR0-12, lanreotide versus placebo
- −2.9 %/month
- 12 weeks
- 95% CI of difference in TGR0-12
- −5.1 to −0.8 %/month
- 12 weeks
- P value for TGR0-12 difference
- 0.008
- 12 weeks
Source sentences
TGR was significantly reduced by 12 weeks with lanreotide versus placebo (difference in least-square mean TGR0-12 of - 2.9 [- 5.1, - 0.8], p = 0.008), a difference that was maintained at most subsequent visits.
2 context sentences(design, population, supporting numbers)
During CLARINET, patients with metastatic intestinal/pancreatic NETs received lanreotide depot/autogel 120 mg or placebo every 4 weeks for 96 weeks.
Imaging data (response evaluation criteria in solid tumors [RECIST] v1.0, centrally reviewed) were re-evaluated in this post hoc analysis of tumor growth rate (TGR) in NETs.